Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria: A Feasibility Study

Next Previous
Trial Profile

Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria: A Feasibility Study

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 06 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 31 Jan 2023 Planned End Date changed from 17 Dec 2026 to 31 Oct 2027.
  • 31 Jan 2023 Planned primary completion date changed from 17 Jun 2026 to 30 Apr 2027.
  • 02 Jul 2022 An interim analysis will be performed is to assess the feasibility and safety after 20 patients become evaluable. The study is open with 30 patients enrolled at the time of submission as per trial design presented at the 24th World Congress on Gastrointestinal Cancer

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top